obesity drug news today glp-1 oct 27 2025 Pharma Giants Bet on Next-Generation Treatments to Sustain Growth GLP-1 therapies are changing obesity
Description
Youve likely heard about glucagon-like peptide-1 agonists commonly referred to as GLP-1 medications, and more widely recognized through pharmaceutical brand names like Ozempic and Mounjaro.
Key Benefits & Features
Yet, data on their safety and clinical utility during these reproductive windows remain limited
Given the potential for increased INR variability, clinicians may consider increasing INR monitoring frequency following GLP-1 RA initiation.
As a scientist, its exciting to conduct research at this scaleusing millions of real-world data points to uncover measurable patterns and actionable insights
Supports healthy blood sugar metabolism*
